PMA device
AGENT Paclitaxel-Coated Balloon Catheter
Boston Scientific Corporation · Drug-Eluting Percutaneous Transluminal Coronary Angioplasty Catheter (OOB, Class III) · First FDA decision Feb 29, 2024, newest Feb 11, 2026Coronary artery disease
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
4
Breakthrough-designated
Device trials
207
Naming "AGENT Paclitaxel-Coated"
MAUDE reports
0
Brand "AGENT Paclitaxel-Coated", since 2015
PubMed studies
7
Mentioning "AGENT Paclitaxel-Coated"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing AGENT Paclitaxel-Coated Balloon Catheter
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 4 of 4 decisions filed under this name.
- AGENT Paclitaxel-Coated Balloon CatheterPMA supplement
P230035-S006 · Decided Feb 11, 2026 · 265 days after receipt · Normal 180 Day Track No User Fee
Device type: Drug-eluting percutaneous transluminal coronary angioplasty catheter (OOB) · Cardiology
- AGENT Paclitaxel-Coated Balloon CatheterPMA supplement
P230035-S002 · Decided Jun 28, 2024 · 28 days after receipt · Normal 180 Day Track No User Fee
Device type: Drug-eluting percutaneous transluminal coronary angioplasty catheter (OOB) · Cardiology
- AGENT Paclitaxel-Coated Balloon CatheterPMA supplement
P230035-S001 · Decided Apr 11, 2024 · 28 days after receipt · Normal 180 Day Track No User Fee
Device type: Drug-eluting percutaneous transluminal coronary angioplasty catheter (OOB) · Cardiology
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R8Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R7Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R6Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R3Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) and Stenting of the Renal ArteriesNational analysisReview closedCAG-00085R4Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085NUpdated Sep 15, 2026
- Percutaneous Transluminal Angioplasty (PTA)National determinationOn the books20.7Updated May 14, 2025
- Cardiac Catheterization and Coronary AngiographyLocal determinationIn effectL33959CGS Administrators, LLCUpdated Oct 30, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "AGENT Paclitaxel-Coated", any status and sponsor, newest update first.
- Comparison of Fractional FLOW Reserve Outcomes With Drug-Coated Balloon-Based Versus Drug-Eluting Stent-Only Percutaneous Coronary Intervention StrategiesPivotal-lookingRecruiting
Korea University Guro HospitalAcademic, hospital or other
NCT07852689 · 100 participants (planned) · Start Nov 16, 2026 · Primary completion Sep 30, 2028
Device: Drug-coated balloon-based intervention; Drug-eluting stent-based intervention · For: Coronary Artery Disease; Percutaneous Coronary Intervention; Drug Coated Balloon and 3 more
Sites: Seoul, South Korea · 4 sites in all
Boston Scientific CorporationPublic (BSX)
NCT04674969 · 5,000 participants (planned) · Start Mar 29, 2021 · Primary completion Jan 2028
Device: Any eligible commercially available Boston Scientific Corporation (BSC) drug-eluting device. · For: Peripheral Vascular Diseases
Sites: Jonesboro, Arkansas; Los Angeles, California; Sacramento, California · 89 sites in all
- Sirolimus-Coated Versus Paclitaxel-Coated Balloon for Recurrent Coronary In-Stent Restenosis After Prior Paclitaxel-Coated Balloon Treatment (SPRIT)Pivotal-lookingNot yet recruiting
Sir Run Run Shaw HospitalAcademic, hospital or other
NCT07920055 · 106 participants (planned) · Start Nov 1, 2026 · Primary completion Aug 31, 2028
Device: SeQuent SCB sirolimus-coated balloon · For: Coronary In-stent Restenosis; Coronary Artery Disease
Sites: Hangzhou, China
204 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "AGENT Paclitaxel-Coated", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code OOB
673 reports: 388 malfunction, 208 injury, 76 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "AGENT Paclitaxel-Coated"[tiab]. The summary above synthesizes these.
- Paclitaxel-Coated Balloon for the Treatment of Multilayer In-Stent Restenosis: AGENT IDE Subgroup Analysis.
Kirtane AJ, Shlofmitz R, Moses J, et al. · J Am Coll Cardiol · 2025Randomized Controlled Trial, Multicenter Study
- Paclitaxel-Coated Balloon for the Treatment of Small Vessel In-Stent Restenosis: A Subgroup Analysis of the AGENT IDE Randomized Trial.
Wen J, Dohad S, Shlofmitz R, et al. · JACC Cardiovasc Interv · 2025Clinical Trial, Phase III, Comparative Study
- Percutaneous Coronary Intervention With the Agent Paclitaxel-Coated Balloon: A Real-World Multicenter Experience.
Iannopollo G, Giannini F, Ponticelli F, et al. · J Invasive Cardiol · 2020Multicenter Study
- One-year safety and effectiveness of the Agent paclitaxel-coated balloon for the treatment of small vessel disease and in-stent restenosis.
Nakamura M, Isawa T, Nakamura S, et al. · Cardiovasc Interv Ther · 2024Randomized Controlled Trial
- Paclitaxel-Coated Balloon for Treating In-Stent Restenosis in Racial and Ethnic Minority Patients: A Subanalysis From the AGENT IDE Trial.
Jamil Y, Kirtane A, Yeh RW, et al. · J Am Heart Assoc · 2026Clinical Trial, Phase III, Comparative Study
- Patient-Specific 3D Coronary Reconstruction and Computational Simulations to Guide Drug-Coated Balloon Intervention: First-in-Human Experience.
Wu W, Bhat RR, Zhao S, et al. · JACC Case Rep · 2026Case Reports
- Predictors of Target Lesion Failure in Patients With In-Stent Restenosis: Insights From the AGENT IDE Trial.
Abbott JD, Kassis N, Latib A, et al. · Circ Cardiovasc Interv · 2026Randomized Controlled Trial, Multicenter Study
Other devices of this type
Also filed under product code OOB.
- SELUTION SLR 014 PTCA Drug-Eluting BalloonMedAlliance, LLC · PMA 2026
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.